Amneal Pharmaceuticals, Inc. (AMRX) Financials
AMRX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 3.8 billion | 3.7 billion |
| March 31, 2026 | 3.5 billion | 3.6 billion |
| Dec. 31, 2025 | 3.7 billion | 3.7 billion |
| Sept. 30, 2025 | 3.6 billion | 3.7 billion |
AMRX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -64.9 million | 10.4 million |
| March 31, 2026 | -42.6 million | 8.8 million |
| Dec. 31, 2025 | 87.1 million | 8.2 million |
| Sept. 30, 2025 | 103.4 million | 8.2 million |
AMRX Net Income
No data available :(
AMRX Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 127.6 million | 2.6 billion | 121.5 million |
| March 31, 2026 | 197.7 million | 2.6 billion | 124.7 million |
| Dec. 31, 2025 | 310.9 million | 2.6 billion | 102.4 million |
| Sept. 30, 2025 | 201.2 million | 2.6 billion | 112.0 million |
AMRX Shares Outstanding
AMRX Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 45.6 million | 41.1 million | 148.7 million | - |
| March 31, 2026 | 13.9 million | 38.4 million | 138.9 million | - |
| Dec. 31, 2025 | 43.2 million | 34.8 million | 146.5 million | - |
| Sept. 30, 2025 | 15.1 million | 63.4 million | 137.8 million | - |
AMRX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 796.2 million | 461.7 million |
| March 31, 2026 | 722.5 million | 402.4 million |
| Dec. 31, 2025 | 814.3 million | 517.1 million |
| Sept. 30, 2025 | 784.5 million | 510.5 million |
AMRX Revenue by Segment
Graph available only for paid members. Upgrade to see it.
AMRX
Price: $20.50
52 week price:
Payout Ratio Range:
Earnings Per Share: 0.48 USD
P/E Ratio: 38.46
Exchange: NMS
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Volume: 1.8 million
Market Capitalization: 5.6 billion